| |
New investments in health tech have set the stage for industry players and revolutionary AI in imaging, drug discovery, digital therapeutics, and more.
Download our whitepaper for trends industry experts believe will shape the virtual care landscape. 
|
|
Today’s Big NewsSep 26, 2023 |
| By Zoey Becker The company inked the buyout at $19 per share after two FDA rejections for Ocaliva in nonalcoholic steatohepatitis-related liver fibrosis and a recent attempt at cutting costs. |
|
|
|
By Nick Paul Taylor Ionis’ phase 3 lipid-lowering clinical trial has hit its primary endpoint, positioning it to file for an approval that would set up its first independent commercial launch. The study linked the high dose to a significant reduction in triglyceride levels and a 100% drop in acute pancreatitis events compared to placebo. |
By Conor Hale The mystery company at the center of a European Union antitrust investigation has been revealed to be Edwards Lifesciences, according to a report from Reuters. |
By Kevin Dunleavy As coronavirus concerns increase with the changing of the seasons, the most commonly used oral antiviral treatments are in the spotlight once again. |
|
Tuesday, October 3, 2023 | 11am ET / 8am PT The life science industry has been growing rapidly. As a result, many biopharma companies are choosing to outsource their analytical method development and testing to CDMOs to fully meet their objectives and foster innovation. Join us to take a deep dive into these critical partnerships and learn key actionable insights. Register now. 
|
|
By Max Bayer Roivant CEO Matt Gline learned just days into his new gig in 2021 that immunology offshoot Immunovant had a cholesterol problem with its lead asset. Now, the concern that sent him immediately spiraling into "crisis management mode" has come full circle, as a next-gen candidate nailed key biomarker figures in a phase 1 trial. |
By Eric Sagonowsky The preliminary settlement deal comes after Gilead and Teva, a generics giant, prevailed in a high-stakes jury trial this summer. |
By Andrea Park A storm may be brewing in the medtech industry, as manufacturer Zeus Company is reportedly planning to bring the thunder in a sale to a new owner. |
By James Waldron With scientific research this year continuing to point to the potential of the PIKFYVE enzyme as a target for amyotrophic lateral sclerosis (ALS), Takeda has decided to join the team. |
By Fraiser Kansteiner On a €1 billion quest to build a global mRNA network, Merck KGaA’s MilliporeSigma has rounded out its service offerings to include all key stages of mRNA development, manufacturing and commercialization. |
By Nick Paul Taylor Johnson & Johnson’s multiple myeloma team wants to “Make It HAPPen.” Working with a professional society, the drugmaker is stepping up its support for advanced practice providers (APPs) guided by survey data showing the key role they play in the multiple myeloma care pathway. |
By Angus Liu,Kevin Dunleavy,Eric Sagonowsky In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Ben Adams Arcutis may still be waiting for a green light from the FDA for its seborrheic dermatitis therapy, but it’s wasting no time in getting the message out about this little-known condition. |
By Andrea Park Hot on the heels of study data showing that its cuffless blood pressure monitor is well on its way to reaching desired accuracy levels, Rockley Photonics is boasting similar progress in the development of another of its biosensor technologies—this one to monitor blood sugar levels for people with diabetes. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we shine a spotlight on some of the most promising companies in the biotech world and do a deep dive into drug commercialization strategies. |
|
|---|
|
|
|
Thursday, October 5, 2023 | 11am ET / 8am PT Viral vectors used in gene therapies face complex and multifaceted analytical challenges. Developing standardized and validated analytical methods, reference standards, and reagents are critical to overcoming these challenges. Join us to learn how to accelerate the development and translation of safe and effective viral vector-based gene therapies with next-generation analytics. Register now. .png)
|
|
Whitepaper As the field of real-world data and evidence is constantly evolving, it can be hard to keep-up with best practices. Do you know the definitive characteristics of a high-quality dataset? What questions to ask if you decide to outsource your research to consultants? Here’s everything you need to know in one, must-have guide. Sponsored by: MarketScan by Merative |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
